APNHY vs BIOVF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APNHY is a Hold and BIOVF is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
APNHY’s FA Score shows that 1 FA rating(s) are green whileBIOVF’s FA Score has 1 green FA rating(s).
- APNHY’s FA Score: 1 green, 4 red.
- BIOVF’s FA Score: 1 green, 4 red.
Price Growth
APNHY (@Pharmaceuticals: Other) experienced а -6.56% price change this week, while BIOVF (@Pharmaceuticals: Other) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -5.07%. For the same industry, the average monthly price growth was -7.87%, and the average quarterly price growth was -11.90%.
Industries' Descriptions
@Pharmaceuticals: Other (-5.07% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| APNHY | BIOVF | APNHY / BIOVF | |
| Capitalization | 4.83B | 5.81B | 83% |
| EBITDA | 7.98B | 6.96B | 115% |
| Gain YTD | -12.035 | 19.543 | -62% |
| P/E Ratio | 14.73 | 19.92 | 74% |
| Revenue | 38.4B | 20.1B | 191% |
| Total Cash | 8.05B | 790M | 1,018% |
| Total Debt | 26.8B | 28.2B | 95% |
APNHY | BIOVF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 17 Undervalued | 83 Overvalued | |
PROFIT vs RISK RATING 1..100 | 70 | 23 | |
SMR RATING 1..100 | 98 | 69 | |
PRICE GROWTH RATING 1..100 | 64 | 40 | |
P/E GROWTH RATING 1..100 | 71 | 72 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
APNHY's Valuation (17) in the null industry is significantly better than the same rating for BIOVF (83). This means that APNHY’s stock grew significantly faster than BIOVF’s over the last 12 months.
BIOVF's Profit vs Risk Rating (23) in the null industry is somewhat better than the same rating for APNHY (70). This means that BIOVF’s stock grew somewhat faster than APNHY’s over the last 12 months.
BIOVF's SMR Rating (69) in the null industry is in the same range as APNHY (98). This means that BIOVF’s stock grew similarly to APNHY’s over the last 12 months.
BIOVF's Price Growth Rating (40) in the null industry is in the same range as APNHY (64). This means that BIOVF’s stock grew similarly to APNHY’s over the last 12 months.
APNHY's P/E Growth Rating (71) in the null industry is in the same range as BIOVF (72). This means that APNHY’s stock grew similarly to BIOVF’s over the last 12 months.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RMYAX | 9.70 | -0.03 | -0.31% |
| Russell Inv Multi-Strategy Income A | |||
| CEMGX | 12.24 | -0.06 | -0.49% |
| Cullen Emerging Markets High Div C | |||
| GTTIX | 22.74 | -0.12 | -0.52% |
| Gabelli Global Content & Connect I | |||
| TGRIX | 12.24 | -0.18 | -1.45% |
| American Century International Gr I | |||
| VHCAX | 203.69 | -3.75 | -1.81% |
| Vanguard Capital Opportunity Adm | |||
APNHY and
Correlation & Price change
A.I.dvisor tells us that APNHY and TRUFF have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APNHY and TRUFF's prices will move in lockstep.
| Ticker / NAME | Correlation To APNHY | 1D Price Change % | ||
|---|---|---|---|---|
| APNHY | 100% | N/A | ||
| TRUFF - APNHY | 21% Poorly correlated | N/A | ||
| NXSCF - APNHY | 20% Poorly correlated | -3.18% | ||
| PRFX - APNHY | 20% Poorly correlated | +2.08% | ||
| ESALF - APNHY | 20% Poorly correlated | -6.56% | ||
| SDZNY - APNHY | 20% Poorly correlated | +1.70% | ||
More | ||||
BIOVF and
Correlation & Price change
A.I.dvisor tells us that BIOVF and INNPF have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BIOVF and INNPF's prices will move in lockstep.
| Ticker / NAME | Correlation To BIOVF | 1D Price Change % | ||
|---|---|---|---|---|
| BIOVF | 100% | N/A | ||
| INNPF - BIOVF | 20% Poorly correlated | +2.12% | ||
| APNHY - BIOVF | 19% Poorly correlated | N/A | ||
| BIOGY - BIOVF | 11% Poorly correlated | N/A | ||
| BMMJ - BIOVF | 6% Poorly correlated | -24.07% | ||
| BOIRF - BIOVF | 1% Poorly correlated | N/A | ||
More | ||||